Agree Ragingboom, let's review PrIME's advantages as follows,...

Agree Ragingboom, let's review PrIME's advantages as follows, the singapore project is valued at NPV $69m, NSP's 50% free carried interest is $34m, circa 32c per share, already exceed 30c, expanding to other Asian country will significantly increse the PrIME project value, if NSP still remains 50% interest for each country, the upside potential is huge.

Now NSP's LOGO, head poffice location are all similar with Cochlear (ASX COH) I am interested to see whether NSP is also growing like Cochlear!

Quote:

1.Doubles the Finished Product Yield

The PrIME process regularly doubles the yield of finished therapeutic plasma products relative to the existing processes. The existing processes at best recovers approximately 50% of the total therapeutic product from the source plasma. By comparison the PrIME process recovers over 90% of the therapeutic product from the plasma feedstock. This means that the PrIME process can produce nearly twice the amount of end product compared to the existing process and therefore requires less plasma to produce the same amount.

2.Ability to process Currently Unprocessable Plasma

The PrIME process can also process plasma that has not been collected in compliance with US FDA regulations. This plasma is normally discarded as it cannot be transferred across country borders. The PrIME process is based on a disposable batch process system that reduces the potential for contamination from one batch to the next. This enables the PrIME to process this Currently Unprocessable Plasma, further increasing the supply of therapeutic plasma products from the limited plasma supply.

3.Greater Safety provided by the PrIME Process

The PrIME technology is an electrically driven membrane separation process (Electrophoresis) and offers an additional and more efficient method to remove pathogens, viruses and other toxins from the source plasma. The pathogen studies have demonstrated that the PrIME process offers an additional 4 log reduction of virus and significant log reduction of prions from plasma. Thus using the PrIME process contributes added safety to the end product of the manufacturing process.

4.Lower Capital Cost

The existing fractionation processes are capital intensive. The smallest economically feasible fractionation process that can be built using the existing technology will cost approximately US$100m for a 100,000L facility. The PrIME process is modular and can be built to process from 10,000L upwards. A basic 50,000L facility will cost approximately US$20m. The therapeutic product that this 50,000L facility can produce is in excess of US$30m pa.

5.Broader Range of Therapeutic Products

The PrIME process offers a selective and higher yielding fractionation of the plasma than the existing process. As a result, the PrIME process enables a higher yield and a greater number of therapeutic products to be produced from a given litre of plasma than the existing processes.